论文部分内容阅读
目的观察多西他赛联合卡培他滨对局部晚期胃癌的疗效。方法选取50例局部晚期胃癌患者,给予多西他赛联合卡培他滨方案治疗(观察组),同时选取50例单用多西他赛治疗的患者作为对照组,观察两组患者近期疗效、生存率及化疗不良反应等。结果观察组患者近期治疗有效率为70.0%,对照组为56.0%,差异有统计学意义(P<0.05)。观察组患者的1、2、3年生存率分别为74.0%、56.0%和52.0%,对照组患者的1、2、3年生存率分别为54.0%、40.0%和28.0%,差异有统计学意义(P<0.05)。骨髓抑制与消化道反应是较为多见的不良反应,但两组PLT计数降低、WBC计数降低、肝肾损害、腹泻、呕吐恶心、脱发等方面差异均无统计学意义(P>0.05)。结论多西他赛联合卡培他滨治疗局部晚期胃癌近期临床效果较佳,且不良反应发生率较低。
Objective To observe the effect of docetaxel and capecitabine on locally advanced gastric cancer. Methods Fifty patients with locally advanced gastric cancer were selected and treated with docetaxel combined with capecitabine (observation group). Fifty patients treated with docetaxel alone were selected as control group. The curative effect, Survival rate and chemotherapy adverse reactions. Results The effective rate of the treatment in the observation group was 70.0% and that in the control group was 56.0%, the difference was statistically significant (P <0.05). The 1, 2, 3-year survival rates of the observation group were 74.0%, 56.0% and 52.0%, respectively. The 1, 2, 3-year survival rates of the control group were 54.0%, 40.0% and 28.0% Significance (P <0.05). Myelosuppression and gastrointestinal reactions were more common adverse reactions. However, there was no significant difference in PLT count, WBC count, liver and kidney damage, diarrhea, nausea and hair loss in both groups (P> 0.05). Conclusion Docetaxel combined with capecitabine in the treatment of locally advanced gastric cancer has a better clinical effect and a lower incidence of adverse reactions.